Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 15.11
SGNT's Cash to Debt is ranked higher than
76% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. SGNT: 15.11 )
SGNT' s 10-Year Cash to Debt Range
Min: 1.66   Max: No Debt
Current: 15.11

Equity to Asset 0.76
SGNT's Equity to Asset is ranked higher than
80% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. SGNT: 0.76 )
SGNT' s 10-Year Equity to Asset Range
Min: -1.15   Max: 0.77
Current: 0.76

-1.15
0.77
Interest Coverage 33.74
SGNT's Interest Coverage is ranked higher than
62% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 90.51 vs. SGNT: 33.74 )
SGNT' s 10-Year Interest Coverage Range
Min: 33.74   Max: 9999.99
Current: 33.74

33.74
9999.99
F-Score: 7
Z-Score: 6.66
M-Score: -2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 12.82
SGNT's Operating margin (%) is ranked higher than
80% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. SGNT: 12.82 )
SGNT' s 10-Year Operating margin (%) Range
Min: -258.05   Max: 12.82
Current: 12.82

-258.05
12.82
Net-margin (%) 12.09
SGNT's Net-margin (%) is ranked higher than
82% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. SGNT: 12.09 )
SGNT' s 10-Year Net-margin (%) Range
Min: -253.66   Max: 12.09
Current: 12.09

-253.66
12.09
ROE (%) 12.54
SGNT's ROE (%) is ranked higher than
87% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SGNT: 12.54 )
SGNT' s 10-Year ROE (%) Range
Min: -40.18   Max: 12.54
Current: 12.54

-40.18
12.54
ROA (%) 9.54
SGNT's ROA (%) is ranked higher than
91% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.95 vs. SGNT: 9.54 )
SGNT' s 10-Year ROA (%) Range
Min: -59.67   Max: 9.54
Current: 9.54

-59.67
9.54
ROC (Joel Greenblatt) (%) 37.29
SGNT's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.63 vs. SGNT: 37.29 )
SGNT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3469.43   Max: 37.29
Current: 37.29

-3469.43
37.29
Revenue Growth (%) -40.00
SGNT's Revenue Growth (%) is ranked lower than
57% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SGNT: -40.00 )
SGNT' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 46.4
Current: -40

0
46.4
» SGNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SGNT Guru Trades in Q1 2013

Steven Cohen Sold Out
» More
Q2 2013

SGNT Guru Trades in Q2 2013

Jim Simons 10,200 sh (New)
Steven Cohen 5,136 sh (New)
» More
Q3 2013

SGNT Guru Trades in Q3 2013

Jim Simons 56,600 sh (+454.9%)
Steven Cohen 24,130 sh (+369.82%)
» More
Q4 2013

SGNT Guru Trades in Q4 2013

NWQ Managers 675,935 sh (New)
Joel Greenblatt 39,358 sh (New)
Jim Simons 98,500 sh (+74.03%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SGNT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 New Buy0.02%$20.25 - $25.39 $ 21.03-7%39358
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.60
SGNT's P/E(ttm) is ranked higher than
75% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. SGNT: 20.60 )
SGNT' s 10-Year P/E(ttm) Range
Min: 18.76   Max: 473.95
Current: 20.6

18.76
473.95
P/B 2.90
SGNT's P/B is ranked higher than
62% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. SGNT: 2.90 )
SGNT' s 10-Year P/B Range
Min: 2.49   Max: 5.06
Current: 2.9

2.49
5.06
P/S 2.60
SGNT's P/S is ranked higher than
60% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. SGNT: 2.60 )
SGNT' s 10-Year P/S Range
Min: 0.46   Max: 3.44
Current: 2.6

0.46
3.44
PFCF 14.90
SGNT's PFCF is ranked higher than
85% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.79 vs. SGNT: 14.90 )
SGNT' s 10-Year PFCF Range
Min: 13.15   Max: 69.27
Current: 14.9

13.15
69.27
EV-to-EBIT 16.90
SGNT's EV-to-EBIT is ranked higher than
68% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. SGNT: 16.90 )
SGNT' s 10-Year EV-to-EBIT Range
Min: 15   Max: 331.9
Current: 16.9

15
331.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.20
SGNT's Price/Net Cash is ranked higher than
63% of the 219 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.70 vs. SGNT: 8.20 )
SGNT' s 10-Year Price/Net Cash Range
Min: 9.84   Max: 18.93
Current: 8.2

9.84
18.93
Price/Net Current Asset Value 5.30
SGNT's Price/Net Current Asset Value is ranked higher than
70% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. SGNT: 5.30 )
SGNT' s 10-Year Price/Net Current Asset Value Range
Min: 6.26   Max: 7.19
Current: 5.3

6.26
7.19
Price/Tangible Book 3.00
SGNT's Price/Tangible Book is ranked higher than
63% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. SGNT: 3.00 )
SGNT' s 10-Year Price/Tangible Book Range
Min: 3.54   Max: 4.3
Current: 3

3.54
4.3
Price/Median PS Value 1.00
SGNT's Price/Median PS Value is ranked higher than
68% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. SGNT: 1.00 )
SGNT' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 1.26
Current: 1

0.44
1.26
Price/Graham Number 1.70
SGNT's Price/Graham Number is ranked higher than
69% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. SGNT: 1.70 )
SGNT' s 10-Year Price/Graham Number Range
Min: 2.1   Max: 2.1
Current: 1.7

Earnings Yield (Greenblatt) 5.90
SGNT's Earnings Yield (Greenblatt) is ranked higher than
73% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. SGNT: 5.90 )
SGNT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 6.7
Current: 5.9

0.3
6.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S06.Germany
Sagent Pharmaceuticals Co is a pharmaceutical company engaged in developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.
» More Articles for SGNT

Headlines

Articles On GuruFocus.com

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide